Publications by authors named "F Kouri"
Article Synopsis
- Glioblastoma (GBM) is hard to treat due to the challenges posed by blood-brain barriers and a lack of targeted therapies.
- Researchers developed a new treatment using spherical nucleic acids (SNAs) made of gold nanoparticles that deliver siRNA to target a specific GBM oncogene, Bcl2L12.
- A clinical trial showed that this approach is safe, allows the SNAs to penetrate tumors, and leads to a decrease in the target protein in glioma cells, marking a promising step for GBM treatment.
Isocitrate dehydrogenases (IDHs) are critical metabolic enzymes that catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate (αKG), NAD(P)H, and CO. IDHs epigenetically control gene expression through effects on αKG-dependent dioxygenases, maintain redox balance and promote anaplerosis by providing cells with NADPH and precursor substrates for macromolecular synthesis, and regulate respiration and energy production through generation of NADH. Cancer-associated mutations in and represent one of the most comprehensively studied mechanisms of IDH pathogenic effect.
View Article and Find Full Text PDFArticle Synopsis
- Mutations or increased expression of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) are linked to cancer progression through changes in metabolism and gene expression. !* -
- IDH3α, a subunit of the IDH3 enzyme, is found at higher levels in glioblastoma (GBM) samples and contributes to tumor growth in mouse models. !* -
- IDH3α influences cellular energy production and nucleotide availability during DNA replication while its loss affects methionine metabolism, indicating a new metabolic adaptation mechanism in GBM. !*
Article Synopsis
- Oncogenic mutations in IDH1 and IDH2 genes are linked to various cancers, including acute myelogenous leukemia and glioblastomas.
- Research shows that non-mutated IDH1 is frequently overexpressed in primary GBMs, and inhibiting IDH1 can slow down tumor growth and increase cell death in these cancers.
- The study indicates IDH1 plays a key role in cancer metabolism, and its upregulation allows GBMs to thrive by supporting growth and resisting treatments.